Severe Symptomatic Hypocalcemia after Denosumab Administration in an End-Stage Renal Disease Patient on Peritoneal Dialysis with Controlled Secondary Hyperparathyroidism [PDF]
, 2019 Agarwal, Mohit +6 more
core
Mechanisms of Chemotherapy-Induced Diarrhoea [PDF]
, 2017 Davies, A, French, S, Pirmohamed, M
core +1 more source
Efficacy and safety of curettage with bone grafting combined with denosumab in the treatment of distal radius giant cell tumor of bone. [PDF]
Medicine (Baltimore)Yang H, Li S, Zhang Y, Wu S.
europepmc +1 more source
Real-life use of bone-targeting agents for bone metastases in France between 2009 and 2018: Results of the OPTIMOS study. [PDF]
J Bone OncolConfavreux CB +8 more
europepmc +1 more source
Perils and Promises of Therapeutic Approaches for the Stem Cell Disease Fibrous Dysplasia [PDF]
, 2019 Saggio, Isabella
core +1 more source
Proteomic analysis of osteoblasts secretome provides new insights in mechanisms underlying osteoarthritis subchondral bone sclerosis [PDF]
, 2018 Comblain, Fanny +5 more
core +1 more source
European Medicines Agency approvals of new medicines in September and October 2025. [PDF]
Lancet Reg Health EurSepodes B, Burgos JG, Thirstrup S.
europepmc +1 more source
Cardiovascular adverse events associated with denosumab versus zoledronic acid in patients with breast cancer: a propensity score overlap weighted analysis. [PDF]
Breast Cancer Res TreatIwai C +6 more
europepmc +1 more source
Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS) [PDF]
Ruibo Li +4 more
openalex +1 more source